1. Home
  2. RNP vs MDXG Comparison

RNP vs MDXG Comparison

Compare RNP & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNP
  • MDXG
  • Stock Information
  • Founded
  • RNP 2003
  • MDXG 2006
  • Country
  • RNP United States
  • MDXG United States
  • Employees
  • RNP N/A
  • MDXG N/A
  • Industry
  • RNP Investment Managers
  • MDXG Biotechnology: Pharmaceutical Preparations
  • Sector
  • RNP Finance
  • MDXG Health Care
  • Exchange
  • RNP Nasdaq
  • MDXG Nasdaq
  • Market Cap
  • RNP 1.0B
  • MDXG 1.0B
  • IPO Year
  • RNP N/A
  • MDXG N/A
  • Fundamental
  • Price
  • RNP $21.20
  • MDXG $7.19
  • Analyst Decision
  • RNP
  • MDXG Buy
  • Analyst Count
  • RNP 0
  • MDXG 1
  • Target Price
  • RNP N/A
  • MDXG $12.00
  • AVG Volume (30 Days)
  • RNP 117.6K
  • MDXG 749.2K
  • Earning Date
  • RNP 01-01-0001
  • MDXG 10-29-2025
  • Dividend Yield
  • RNP 7.94%
  • MDXG N/A
  • EPS Growth
  • RNP N/A
  • MDXG N/A
  • EPS
  • RNP N/A
  • MDXG 0.27
  • Revenue
  • RNP N/A
  • MDXG $393,442,000.00
  • Revenue This Year
  • RNP N/A
  • MDXG $12.68
  • Revenue Next Year
  • RNP N/A
  • MDXG $8.18
  • P/E Ratio
  • RNP N/A
  • MDXG $26.62
  • Revenue Growth
  • RNP N/A
  • MDXG 14.77
  • 52 Week Low
  • RNP $15.52
  • MDXG $5.69
  • 52 Week High
  • RNP $21.27
  • MDXG $10.14
  • Technical
  • Relative Strength Index (RSI)
  • RNP 34.72
  • MDXG 60.88
  • Support Level
  • RNP $21.44
  • MDXG $6.68
  • Resistance Level
  • RNP $21.88
  • MDXG $6.86
  • Average True Range (ATR)
  • RNP 0.30
  • MDXG 0.23
  • MACD
  • RNP -0.01
  • MDXG 0.04
  • Stochastic Oscillator
  • RNP 8.11
  • MDXG 82.11

About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.

Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.

About MDXG MiMedx Group Inc

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Share on Social Networks: